KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 17654 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes. PMID 40544432 · N Engl J Med · 2025-Aug-14 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Addition of Dendritic Cell Vaccination to Conditioning Cyclophosphamide and Chemoembolization in Patients with Hepatocellular Carcinoma: The ImmunoTACE Trial. PMID 40499144 · Clin Cancer Res · 2025-Aug-14 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Comparative analysis of the use of Community Health Workers while deploying the Attractive Targeted Sugar Bait (ATSB) for malaria control in Western Province, Zambia. PMID 40804418 · Malar J · 2025-Aug-13 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Textbook outcome in low rectal cancer patients undergoing laparoscopic or open surgery: 3-year results from the multicentric LASRE Trial. PMID 40804342 · Int J Colorectal Dis · 2025-Aug-13 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Interventions for anal canal intraepithelial neoplasia. PMID 40801169 · Cochrane Database Syst Rev · 2025-Aug-13 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Design of a multicenter, randomized, double-blinded, placebo-controlled phase III trial evaluating the 9-valent human papillomavirus (HPV) vaccine to prevent persistent oral HPV infection in men living with human immunodeficiency virus: ULACNet trial 201. PMID 40609265 · Vaccine · 2025-Aug-13 The study is a Phase III randomized trial of a drug intervention (vaccine) in oncology (preventing cancer precursor), but it is a protocol publication without results. Furthermore, the primary endpoint (incidence of persistent oral HPV infection) is an infection incidence endpoint, not a time-to-event efficacy endpoint like OS, PFS, or DFS. Therefore, it does not meet the criteria for inclusion in an oncology Kaplan-Meier digitization cohort.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Phase II/III randomized immunogenicity and safety study of a Brazilian meningococcal serogroup B vaccine in children. PMID 40494223 · Vaccine · 2025-Aug-13 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Safety and immunogenicity of four sequential doses of NVX-CoV2373 in adults and adolescents: A phase 3, randomized, placebo-controlled trial (PREVENT-19). PMID 40479932 · Vaccine · 2025-Aug-13 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
The efficacy and safety of SYN023 (Zamerovimab and Mazorelvimab injection), the recombinant humanized anti-rabies virus monoclonal antibody mixture, combined with rabies vaccine in a WHO category III rabies post-exposure population: A randomized, double-blind, positive control, phase III clinical trial. PMID 40479926 · Vaccine · 2025-Aug-13 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Impact of exercise interventions on cardiotoxicity in patients with breast cancer undergoing chemotherapy: a study protocol for a quasi-randomised controlled trial. PMID 40803741 · BMJ Open · 2025-Aug-12 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Surgical Complications in Patients with (borderline) Resectable Pancreatic Cancer after Neoadjuvant Therapy in the PREOPANC-2 Randomized Controlled Trial. PMID 40792645 · Ann Surg · 2025-Aug-12 The study is an oncology RCT with drug interventions, but its primary endpoint is the incidence of major surgical complications, which is a binary safety/morbidity outcome, not a time-to-event efficacy endpoint (e.g., OS, PFS). Therefore, it does not meet the cohort's requirement for a primary/key secondary time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Telemedicine follow-up for pre-malignant and malignant glottic lesions: a randomised controlled trial study protocol comparing care close to home versus standard of care. PMID 40791158 · Acta Oncol · 2025-Aug-12 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Impact of Vutrisiran on Cardiac Biomarkers in Patients With Transthyretin Amyloidosis With Cardiomyopathy From HELIOS-B. PMID 40769675 · J Am Coll Cardiol · 2025-Aug-12 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Effects of Vutrisiran on Cardiac Function and Outcomes in Patients With Transthyretin Amyloidosis With Cardiomyopathy. PMID 40769673 · J Am Coll Cardiol · 2025-Aug-12 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Noncontrast CT vs CT Perfusion Imaging in Patients With Basilar Artery Occlusion: Analysis of the ATTENTION and ATTENTION IA Trials. PMID 40674670 · Neurology · 2025-Aug-12 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Long-term follow-up of MRD-guided ibrutinib plus venetoclax in relapsed CLL: phase 2 VISION/HO141 trial. PMID 40249856 · Blood Adv · 2025-Aug-12 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
A randomized trial to evaluate the pharmacokinetics, pharmacodynamics, and safety of vadadustat in patients with anemia associated with chronic kidney disease receiving hemodialysis. PMID 40790188 · BMC Nephrol · 2025-Aug-11 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Assessing participants' experiences with the COVID-19 symptom diary in a clinical trial. PMID 40788441 · J Patient Rep Outcomes · 2025-Aug-11 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of Neoadjuvant Chemotherapy with or without Immune Checkpoint Inhibitors for Resectable Esophageal Squamous Cell Carcinoma: a Meta-analysis of Randomized Controlled Trials. PMID 40788432 · J Gastrointest Cancer · 2025-Aug-11 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Non-targeted immunosuppressive and immunomodulatory therapies for idiopathic inflammatory myopathies. PMID 40787733 · Cochrane Database Syst Rev · 2025-Aug-11 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Duplex ultrasound after endo revascularisation (DUSTER): protocol for a randomised controlled feasibility trial. PMID 40784780 · BMJ Open · 2025-Aug-10 方案论文未报告临床试验结果。
H
仅历史库存 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Surgery Versus Ablation for Hepatocellular Carcinoma: A Randomized Controlled Trial (SURF-RCT Trial) and a Nonrandomized Prospective Observational Trial (SURF-Cohort Trial). PMID 40554738 · J Clin Oncol · 2025-Aug-10 The study is a randomized oncology trial with time-to-event endpoints, but it compares two surgical/procedural interventions (surgery vs. radiofrequency ablation) and does not involve a drug-containing intervention, which is a required criterion for inclusion.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Impact of Lean Body Mass-Based Oxaliplatin Dose Calculation on Neurotoxicity in Adjuvant Treatment of Stage III Colon Cancer: Results of the Phase II Randomized LEANOX Trial. PMID 40540704 · J Clin Oncol · 2025-Aug-10 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Glofitamab Combined With Pola-R-CHP or R-CHOP as First Therapy in Younger Patients With High-Risk Large B-Cell Lymphoma: Results From the COALITION Study. PMID 40532125 · J Clin Oncol · 2025-Aug-10 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Long-Term Follow-Up of E3311, an ECOG-ACRIN Cancer Research Group Phase II Trial of Transoral Surgery and Risk-Based Adjuvant Treatment in Human Papillomavirus-Initiated Oropharynx Cancer. PMID 40493877 · J Clin Oncol · 2025-Aug-10 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Randomized Phase II Study of Concurrent Versus Sequential Pembrolizumab in Combination With Chemoradiation in Locally Advanced Head and Neck Cancer. PMID 40424564 · J Clin Oncol · 2025-Aug-10 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Clinical Benefit and Safety of Reduced Elective Dose in Definitive Radiotherapy for Head and Neck Squamous Cell Carcinoma: The UPGRADE-RT Multicenter Randomized Controlled Trial. PMID 40233286 · J Clin Oncol · 2025-Aug-10 The record is excluded because it does not meet two key criteria for inclusion: 1) it is a non-drug intervention study (radiotherapy dose comparison, not a drug-containing arm), and 2) it does not have a primary or key secondary time-to-event efficacy endpoint (the primary endpoint is a quality-of-life score, and the secondary is a cumulative incidence, not a time-to-event analysis).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Randomized, phase II trial to evaluate the efficacy and safety of atezolizumab plus capecitabine adjuvant therapy compared to capecitabine monotherapy for triple receptor-negative breast cancer with residual invasive cancer after neoadjuvant chemotherapy (MIRINAE trial, KCSG-BR18-21). PMID 40783751 · BMC Cancer · 2025-Aug-09 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Evaluating the effects of a resistance exercise intervention for sarcopenia in patients receiving neoadjuvant chemotherapy for breast cancer: study protocol for a randomized controlled trial. PMID 40783722 · BMC Cancer · 2025-Aug-09 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Comparing the effectiveness of implementation strategies to improve liver and colon cancer screening for Veterans: protocol for a large cluster-randomized implementation study. PMID 40783525 · Implement Sci · 2025-Aug-09 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Phase II single vs hypofractionated irradiation for timely access to partial breast radiotherapy (SHIFT-PB). PMID 40781619 · BMC Cancer · 2025-Aug-08 The record describes a Phase II randomized controlled trial protocol for a radiation therapy fractionation study, not a report of results from a Phase III/IIIb or definitive Phase II/III randomized trial with drug intervention and time-to-event efficacy endpoints.
H S B
严格 v3 独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Can preoperative CT angiography and three-dimensional reconstruction of the mesenteric artery of the colon improve laparoscopic colectomy and postoperative rehabilitation in patients with colon cancer? A pilot randomized control study. PMID 40779208 · Int J Colorectal Dis · 2025-Aug-08 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
[Interpretation and implications of the phase Ⅲ KEYNOTE-689 trial in head and neck squamous cell carcinoma]. PMID 40890052 · Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi · 2025-Aug-07 The record appears to be a commentary or interpretation article about a Phase III trial, not the original trial report with primary or secondary efficacy results. Without an abstract or clear evidence of reporting trial outcomes, it cannot be considered an eligible primary result report.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Effect of nurse-led intervention programs based on spiritual care on the resilience and death anxiety in parents of children and adolescents with cancer, a randomized clinical trial. PMID 40775798 · BMC Psychol · 2025-Aug-07 Study is a randomized trial in an oncology context but evaluates a non-drug nursing intervention (spiritual care) with psychological endpoints, lacking any drug intervention or time-to-event efficacy endpoint as defined.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
The efficacy and safety of inhaled peptide YKYY017 for COVID-19 patients with mild illness: a phase 2 randomized controlled trial. PMID 40775020 · Nat Commun · 2025-Aug-07 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Implications of the API-CAT Trial for Extended Secondary Prophylaxis of Cancer-associated Venous Thromboembolism: Guidance from an Expert Panel. PMID 40774336 · Hamostaseologie · 2025-Aug-07 The record is an expert consensus/guidance paper on the API-CAT trial, not the original trial report. It discusses VTE recurrence as the efficacy endpoint, which is a safety/prophylaxis endpoint, not a standard oncology efficacy endpoint (OS, PFS, DFS). The report type is secondary (expert consensus).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Ciprofloxacin versus Aminoglycoside-Ciprofloxacin for Bubonic Plague. PMID 40768716 · N Engl J Med · 2025-Aug-07 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Rice-derived recombinant human serum albumin as an alternative to human plasma for patients with decompensated liver cirrhosis: a randomised, double-blind, positive-controlled and non-inferiority trial. PMID 40555465 · Gut · 2025-Aug-07 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Phase II trial of intravenous human dental pulp stem cell therapy for Huntington's disease: a randomized, double-blind, placebo-controlled study. PMID 40770775 · Stem Cell Res Ther · 2025-Aug-06 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Knee arthroplasty compared with joint distraction for osteoarthritis: a phase III randomized controlled trial. PMID 40763924 · Bone Jt Open · 2025-Aug-06 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Clinical effectiveness, safety, and viral mutagenicity of oral favipiravir for COVID-19: results from a community-based, open-label, randomized Phase III trial. PMID 40552814 · Antimicrob Agents Chemother · 2025-Aug-06 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Population pharmacokinetic/pharmacodynamic modeling to optimize aztreonam-avibactam dose regimens for adult patients. PMID 40530972 · Antimicrob Agents Chemother · 2025-Aug-06 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Design of a randomized tobacco cessation trial among FDNY World Trade Center responders in a lung cancer screening program. PMID 40765018 · Addict Sci Clin Pract · 2025-Aug-05 This is a trial protocol for a randomized smoking cessation study integrated into a lung cancer screening program. While it is randomized, involves humans, is oncology-related, and includes a drug (varenicline), it is not a report of results from a Phase III/IIIb or Phase II/III oncology randomized trial with a time-to-event efficacy endpoint. It lacks results and the primary outcomes are not time-to-event.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Heart Rhythm Monitoring Practices, Detection of Atrial Fibrillation, and Effect of Anticoagulation in the ARCADIA Trial. PMID 40728193 · J Am Heart Assoc · 2025-Aug-05 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Impact of Dapagliflozin on Cardiometabolic Outcomes After Acute Myocardial Infarction According to Baseline Glycemic Status and Body Mass Index: Subanalyses of the DAPA-MI Trial. PMID 40728174 · J Am Heart Assoc · 2025-Aug-05 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Lorundrostat in Participants With Uncontrolled Hypertension and Treatment-Resistant Hypertension: The Launch-HTN Randomized Clinical Trial. PMID 40587141 · JAMA · 2025-Aug-05 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Firsekibart versus compound betamethasone in acute gout patients unsuitable for standard therapy: A randomized phase 3 trial. PMID 40814346 · Innovation (Camb) · 2025-Aug-04 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) Trial: Genetic Resource for Precision Nutrition. PMID 40806132 · Nutrients · 2025-Aug-04 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Regorafenib versus local standard of care in patients with grade 2-3 meningioma no longer eligible for loco-regional treatments: a phase II randomized controlled trial (the MIRAGE study). PMID 40759981 · Trials · 2025-Aug-04 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Deciphering differential biomarkers for anti-interleukin-6 receptor and anti-tumour necrosis factor-α treatment response in rheumatoid arthritis by multiomics analysis. PMID 40759562 · RMD Open · 2025-Aug-04 The study is a Phase III randomized trial of drugs (sarilumab vs. adalimumab) in humans, but it is not in oncology (it is in rheumatoid arthritis). It does not report a time-to-event efficacy endpoint (OS, PFS, DFS, etc.); the primary focus is biomarker analysis. Therefore, it is excluded based on the non-oncology criterion.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -